Related references
Note: Only part of the references are listed.HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Ann K. Daly et al.
NATURE GENETICS (2009)
Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis
Natacha Levi et al.
PEDIATRICS (2009)
High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients
Gbenga R. Kazeem et al.
PHARMACOGENETICS AND GENOMICS (2009)
Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example
A. R. Hughes et al.
PHARMACOGENOMICS (2009)
TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole
Ana Alfirevic et al.
PHARMACOGENOMICS (2009)
High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients
Michael Saag et al.
CLINICAL INFECTIOUS DISEASES (2008)
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population
Chaichon Locharernkul et al.
EPILEPSIA (2008)
Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity
Diana Chessman et al.
IMMUNITY (2008)
HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience
Laura J. Waters et al.
AIDS (2007)
Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population
David Zucman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms:: does a DRESS syndrome really exist?
H. Peyriere et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study
A. Rauch et al.
CLINICAL INFECTIOUS DISEASES (2006)
Genetic factors in the predisposition to drug-induced hypersensitivity reactions
M Pirmohamed
AAPS JOURNAL (2006)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
DA Hughes et al.
PHARMACOGENETICS (2004)
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
S Hetherington et al.
LANCET (2002)
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
S Mallal et al.
LANCET (2002)
Share Paper
